Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/12/2019 11:08 PST] Emisphere Technologies, Inc. (OTC:EMIS), Up By 100.00% ($2.43) From $2.430 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/11/2019 11:46 PST] Emisphere Technologies, Inc. (OTC:EMIS), Up By 100.00% ($2.40) From $2.400 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/07/2019 08:35 PST] EMIS Expected to Trade Up After Bullish Patterns Develop
• [01/23/2019 07:37 PST] EMIS Expected to Trade Up After Bullish Patterns Develop
• [01/14/2019 07:43 PST] EMIS Expected to Trade Up After Bullish Patterns Develop
• [01/11/2019 07:45 PST] EMIS Expected to Trade Up After Bullish Patterns Develop